Major advance:antibody J591 selectively targets tumor blood supply
 

This phase 1 trial results indicate that the antibody J591 is not only a probable treatment for prostate but that it can be used as an agent to carry anticancer drugs or radioactive isotopes to selectively target the capilaries feeding blood to a variety of solid tumors:

http://news.med.cornell.edu/wcmc/wcm...02_12_07.shtml

Cancer Treatment Is First to Directly Target Tumor Blood Supply in Patients

Phase I Trial Confirms Targeting Ability of PSMA Antibody Treatment, a Potentially Major Advance in Cancer Care